hydroxychloroquine has been researched along with Diseases of Immune System in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple's disease, fungal infections), rheumatological (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren's syndrome), and other immunological diseases." | 4.98 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. ( Koudriavtseva, T; Plantone, D, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Solé, G | 1 |
| Salort-Campana, E | 1 |
| Pereon, Y | 1 |
| Stojkovic, T | 1 |
| Wahbi, K | 1 |
| Cintas, P | 1 |
| Adams, D | 1 |
| Laforet, P | 1 |
| Tiffreau, V | 1 |
| Desguerre, I | 1 |
| Pisella, LI | 1 |
| Molon, A | 1 |
| Attarian, S | 1 |
| Plantone, D | 1 |
| Koudriavtseva, T | 1 |
| Cooper, WO | 1 |
| Cheetham, TC | 1 |
| Li, DK | 1 |
| Stein, CM | 1 |
| Callahan, ST | 1 |
| Morgan, TM | 1 |
| Shintani, AK | 1 |
| Chen, N | 1 |
| Griffin, MR | 1 |
| Ray, WA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725] | 80 participants (Anticipated) | Observational | 2020-03-20 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Diseases of Immune System
| Article | Year |
|---|---|
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antineoplastic Agents; Antirheumatic | 2018 |
2 other studies available for hydroxychloroquine and Diseases of Immune System
| Article | Year |
|---|---|
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.
Topics: alpha-Glucosidases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti | 2020 |
Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy.
Topics: Adult; Arthritis; Cohort Studies; Congenital Abnormalities; Female; Fetal Death; Follow-Up Studies; | 2014 |